B
Bullisch
Bullisch · 25%IMVT
$16.79
Szenariopreis
$27.900
-0.787 (-2.82%)Zum Schluss
Loading chart…
- Hoch
- 28.790
- Eröffnung
- 28.460
- Volumengewichteter Durchschnittskurs
- 28.17
- Volumen
- 1.77M
- Marktkap.
- 3.80B
- Tief
- 27.830
- Umsatz
- 49.97M
- EV/EBITDA, TTM
- 0.00
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
KI-Analyse of Immunovant Inc (IMVT)
HaltenImmunovant Inc is not a good buy right now due to significant recent setbacks in drug development and declining investor sentiment. The current price is $30.47, down 9.37% over the last five days, and the RSI is at a low 12.81, indicating oversold conditions. The main risk is the halted development of IMVT-1402, which has created uncertainty in the company's future prospects.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Immunovant Inc (IMVT) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -9.03.
Alphio-AI-Kursszenarien für IMVT
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die IMVT halten
Event-Zeitleiste
News
7.010-12PRnewswireKuehn Law Investigates Immunovant Executives for Fiduciary Breaches
7.010-11NewsfilterSBS Investigates Immunovant for Securities Violations
5.010-08stocktwitsIMVT-1402 Study Failure Triggers Market Reaction
7.009-25PRnewswireImmunovant Stock Drops 6% After Study Misses Primary Endpoint
2.009-23CNBCMcDonald's CEO Warns of Inflation Impact on Sales
IMVT FAQ – beantwortet von Alphio AI
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Immunovant Inc is not a good buy right now due to significant recent setbacks in drug development and declining investor sentiment. The current price is $30.47, down 9.37% over the last five days, and the RSI is at a low 12.81, indicating oversold conditions. The main risk is the halted development of IMVT-1402, which has created uncertainty in the company's future prospects.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.